EN DE

Giant Biogene Holding Co Ltd (2367) Fair Value & Analysis

Consumer Defensive · HK · Market cap HK$28.3B (≈ $3.6B)

What is Giant Biogene Holding Co Ltd really worth?

GB Giant Biogene Holding Co Ltd 2367 · HK
PriceHK$26.62
Fair ValueHK$37.27
Upside+40.0%
Quality61/100

A solid business, trading 29% below our fair value of HK$37.27.

Watch Giant Biogene Holding Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

Strengths

✓Highly profitable · 34.7% net margin
✓generates free cash flow
✓Wide moat 92/100

Risks

!Mixed Growth (revenue 5y +35.9 %/yr)
!Mixed vs. peers (7/13)

For context

·2.02% dividend yield
Evidence: High Range HK$29.44 – HK$46.67

Fair value as of: Aug 13, 2026

From 26 valuation models · updated 22 days ago

Fair value updated Aug 13, 2026, revised from HK$37.24 to HK$37.27 (+0.1%) since Aug 5, 2026. Share price −9.5% over the past month.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

  • The price is below even our cautious bear case (HK$29.44). The market is more pessimistic than our downside scenario.
  • Solid quality (61/100) at a price below fair value, the discount is the argument here, not the business quality.

Price vs Fair Value (4 years)

HK$79.15 HK$22.65 Fair Value HK$37.27 Nov 2022 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

46‑month range HK$22.65 – HK$79.15 · fair‑value band HK$29.44 – HK$46.67 · the HK$26.62 price screens below the HK$37.27 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Giant Biogene Holding Co Ltd (2367) currently trades at HK$26.62, while our model-based Fair Value estimate is HK$37.27, implying the stock looks roughly 28.6% undervalued today. The Quality Score stands at 61/100 (solid quality), in the Consumer Defensive sector. Bull case: the Growth Earnings group reads highest at a median of HK$82.57 per share, and 17 of the 26 models we run sit above the HK$26.62 price. Bear case: the Asset-Based group reads lowest at HK$6.26, and 9 of the 26 models stay below the price. Evidence for this calculation is high.

Over the trailing twelve months, Giant Biogene Holding Co Ltd generated revenue of HK$5.5B at a net margin of 34.7%. Revenue declined 19.8% year over year. It earns a return on equity of 22.5%. The balance sheet holds a net cash position of HK$6.3B. Fundamentals as of Aug 13, 2026

Our scenario range runs from HK$29.44 (bear case) to HK$46.67 (bull case); at HK$26.62, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat. The share trades about 58% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at −36% fair-value upside, at 40%, 2367 screens cheaper than that median.

Fair Value models

This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly HK$0.3999 per share, which is 1.1 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
FCF DCF HK$29.42 HK$42.88 HK$85.75 72
Growth DCF HK$28.02 HK$49.77 HK$85.40 71
EPV HK$21.06 HK$23.58 HK$25.78 70
All 26 models by family
DCF Models
FCF DCF HK$29.42 HK$42.88 HK$85.75 72
Owner Earnings HK$29.27 HK$59.03 HK$121.51 66
5Y Revenue Exit HK$16.78 HK$22.44 HK$34.10 68
5Y EBITDA Exit HK$27.63 HK$44.38 HK$77.23 68
5Y P/E Exit HK$33.82 HK$69.86 HK$119.25 63
10Y Revenue Exit HK$20.39 HK$32.41 HK$38.41 63
10Y EBITDA Exit HK$28.56 HK$55.77 HK$103.05 60
10Y P/E Exit HK$33.07 HK$69.10 HK$128.97 56
Earnings-Based
Graham-Dodd HK$12.26 HK$85.53 HK$120.03 61
Lynch FV HK$44.19 HK$63.12 HK$82.06 59
PEG = 1.0 HK$44.19 HK$63.12 HK$82.06 55
EPV HK$21.06 HK$23.58 HK$25.78 70
Dividend Discount
Gordon GGM HK$10.77 HK$22.40 HK$35.54 64
DDM Multi-Stage HK$10.77 HK$18.89 HK$23.51 64
Multiples
P/E Multiple HK$28.41 HK$37.87 HK$47.34 63
P/S Multiple HK$6.24 HK$8.32 HK$10.40 58
P/B Multiple HK$23.00 HK$30.66 HK$38.33 55
EV/EBIT HK$31.41 HK$39.90 HK$48.39 63
EV/EBITDA HK$26.15 HK$32.89 HK$39.63 64
EV/Revenue HK$11.40 HK$13.74 HK$16.08 52
Asset-Based
NCAV (Graham) HK$4.67 HK$6.26 HK$9.34 51
Growth DCF
Growth DCF HK$28.02 HK$49.77 HK$85.40 71
Rev-Margin DCF HK$17.78 HK$24.86 HK$39.86 67
Economic Profit
Residual Income HK$11.60 HK$14.39 HK$40.76 64
ROIC Compounder HK$25.11 HK$34.55 HK$46.90 67
Growth Earnings
Growth-Adj P/E HK$57.80 HK$82.57 HK$107.34 65

Widest divergence: Growth Earnings (HK$82.57) versus Asset-Based (HK$6.26). Highest evidence: FCF DCF (72).

Notify me when 2367 reaches fair value

Put 2367 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 12.7 as of Jul 2, 2026
P/S ratio 4.42 P/E × margin
EPS (TTM) HK$1.13 price ÷ EPS = P/E 12.7
Dividend yield 2.0% payout 47.7%
Net margin 34.7% FY2025
Return on equity 22.5% TTM
More key figures
Profitability
Return on assets (EBIT) 25.9% avg 5y
Operating margin 31.6% TTM
Growth
Revenue (TTM) HK$5.5B TTM
Revenue growth (YoY) −19.8% 3y avg +32.6%
EPS growth (YoY) −37.3%
Balance sheet & cash flow
Free cash flow HK$1.5B FY2025
Net cash HK$6.3B FY2025

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 61/100

Of which business quality 63 · Market factors (momentum, volatility) 29

Profitability 75
Margins and returns on capital today
Quality Growth 16
Are margins and returns improving?
Cashflow 76
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 23
Disciplined investing over empire-building
Low Volatility 58
Calm price path (market factor)
Momentum 25
Price trend over the last 3–12 months (market factor)
52W Momentum 3
Distance to the 52-week high (market factor)
Net Issuance 47
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Giant Biogene Holding Co., Ltd., an investment holding company, engages in the research, development, manufacture, and sale of bioactive material-based beauty and health products in the People's Republic of China.

Full company description

Giant Biogene Holding Co., Ltd., an investment holding company, engages in the research, development, manufacture, and sale of bioactive material-based beauty and health products in the People's Republic of China. It offers functional skincare products, medical dressings and devices, and functional food products under the KOMFYMED, Collgene, Ke Yu, SKIGIN, and other brands. The company also develops and manufactures rare ginsenosides technology-based functional food products. In addition, it provides aesthetic services. The company was founded in 2000 and is headquartered in Xi'an, the People's Republic of China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Giant Biogene Holding Co Ltd reported revenue of 5.5B CNY in FY2025 versus 1.6B CNY in FY2021, a compound +37.3%/yr. Reported net income was 1.9B CNY in FY2025, compounding +23.3%/yr from FY2021.

Growth Quality 94/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
HK$5.5B
Latest YoY
−0.4%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+32.6%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+35.9%
Avg. revenue growth/yr (6Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+33.9%
Value creation/yr (5Y) ⓘEarnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year.
+18.7% (16.7 + 2.0)
Revenue +37.3%/yr
FY21 1.6B CNY
FY22 2.4B CNY
FY23 3.5B CNY
FY24 5.5B CNY
FY25 5.5B CNY
Net income +23.3%/yr
FY21 828M CNY
FY22 1.0B CNY
FY23 1.5B CNY
FY24 2.1B CNY
FY25 1.9B CNY

Watch 2367: get an alert when its fair value changes →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Giant Biogene Holding Co Ltd · Fair Value
HK$37.27 +29%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Giant Biogene Holding Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2367

Peer Group

Household & Personal Products · 244 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 61 · Above median
Fair Value upside +40% · Top 25%
Return on equity (TTM) 22% · Top 25%
Return on assets 14% · Top 25%
Net margin (TTM) 35% · Top 25%
Operating margin (TTM) 32% · Top 25%
Revenue growth −20% · Bottom 25%
Dividend yield (TTM) 2.0% · Below median

Valuation Multiples vs Household & Personal Products median · lower = cheaper

P/E (TTM) 12.7× · Cheaper than median
P/B 2.85× · Pricier than median
P/S (TTM) 5.12× · Pricier than 75% of peers
P/FCF 2.4× · Pricier than median
EV/EBITDA 10.0× · Pricier than median

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE87 · sector 28
FUTURE0 · sector 8
PAST90 · sector 27
HEALTH0 · sector 98
DIVIDEND40 · sector 56

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Household & Personal Products stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
L'Oréal S.A LORL C$24.76 C$22.64 −9%
Unilever PLC UNA €55.92 €40.47 −28%
Colgate-Palmolive Company CL $90.75 $55.28 −39%
500696 500696 ₹2,093 ₹641.55 −69%
Hindustan Unilever Limited HINDUNILVR ₹2,015 ₹789.46 −61%
Kenvue Inc KVUE $18.95 $10.97 −42%
Kimberly-Clark Corporation KMB $109.55 $79.71 −27%
Henkel AG HEN3 €75.82 €85.95 +13%
The Estée Lauder Companies Inc ESLA €86.54 €18.84 −78%
Church & Dwight Co CHD $101.26 $65.12 −36%

Compare Giant Biogene Holding Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Extrinsic Value Calculator (Options) Splits an option premium into intrinsic and extrinsic (time) value. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is Giant Biogene Holding Co Ltd (2367) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of HK$37.27 versus a price of HK$26.62, about +40% upside (undervalued).
What is the fair value of 2367?
Our model-based fair value for Giant Biogene Holding Co Ltd is HK$37.27 (as of Aug 13, 2026), built from audited fundamentals. The current price: HK$26.62.
What is the quality score of 2367?
Giant Biogene Holding Co Ltd has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Giant Biogene Holding Co Ltd (2367)?
Giant Biogene Holding Co Ltd reported trailing-twelve-month revenue of about HK$5.5B (latest available figure, as of Aug 13, 2026).
What is the net profit margin of 2367?
The net profit margin of Giant Biogene Holding Co Ltd is about 34.7%, meaning it keeps roughly 34.7% of revenue as net income. Based on the latest reported figures.
Does Giant Biogene Holding Co Ltd pay a dividend?
Giant Biogene Holding Co Ltd currently shows a dividend yield of about 2.02% relative to its recent price (as of Aug 13, 2026).
Free · no account needed

Watch Giant Biogene Holding Co Ltd in the live analysis

One click puts Giant Biogene Holding Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.